NUS virtual talk
On 20 October 2021, CPR presented a virtual talk to students pursuing a Master of Science in Biotechnology (Coursework) degree from the National University of Singapore’s Department of Biological Science. Participants comprised local and international adult learners who are keen to deepen their skills and knowledge about the biotechnology industry.
Titled “Unlocking breakthroughs in drug discovery to address global unmet medical needs”, CPR’s presentation was part of a case studies module aimed at providing real-world insights on the technical and entrepreneurial aspects of the biotechnology industry.
The lecture was presented by CPR CEO, Hideaki Shimada and focused on how CPR’s antibody engineering technologies and drug discovery expertise have played an instrumental role in driving the discovery of innovative antibody drugs. During his presentation, he also shared how monoclonal antibody drugs have become an important therapeutic option, with multiple antibody drugs now ranked amongst the world’s top-10 selling drugs.
The lecture ended with a Q&A session where participants had the opportunity to ask more questions about CPR and the biotech scene. Overall, participants found the presentation interesting and appreciated the fresh perspectives of how advancing R&D in this field can help to fight diseases.
